Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 54fludarabine phosphate 48Peripheral Blood Stem Cell Transplantation 37Tacrolimus 36Mycophenolic Acid 35Whole-Body Irradiation 30Busulfan 29Antilymphocyte Serum 26Cyclosporine 23Methotrexate 21fludarabine 19Melphalan 18Filgrastim 18Radiotherapy 13Methylprednisolone 12Etoposide 12Cord Blood Stem Cell Transplantation 12thymoglobulin 11Sirolimus 11Psychiatric Rehabilitation 9Flow Cytometry 9Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Therapeutics 6sargramostim 5ruxolitinib 5Specimen Handling 5Polymerase Chain Reaction 5Cytarabine 5Cyclosporins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × lorvotuzumab mertansine × Lymphoid × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡